Editorial: Novel Drugs Targeting the Microenvironment and the Epigenetic Changes in Hematopoietic Malignancies

Front Pharmacol. 2020 Dec 10:11:614614. doi: 10.3389/fphar.2020.614614. eCollection 2020.

Diana Gulei¹, Ciprian Tomuleasa^{2

3}, Liren Qian⁴, Cristina Bagacean^{5

6}, Carlo M Croce⁷, Gabriel Ghiaur⁸

¹ Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
² Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.
³ Department of Hematology, Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
⁴ Department of Hematology, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China.
⁵ INSERM UMR1227, B lymphocytes and autoimmunity, University of Brest, Brest, France.
⁶ Service d'Hématologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.
⁷ Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, United States.
⁸ Department of Leukemia, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.

No abstract available

Keywords: epigenetic changes; hematological malignances; methylation; pharmacology; tumor microenvionment.

Publication types